Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota. Febuxostat, a potent xanthine oxidase inhibitor, is the first-line drug used for the treatment of hyperuricemia. However, there have...

Full description

Bibliographic Details
Main Authors: Zhen Xiong Zhao, Xiao Hui Tang, Sheng Lu Jiang, Jia Qian Pang, Yu Bin Xu, Dan Dan Yuan, Ling Ling Zhang, Hui Min Liu, Qing Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
hyperuricemic nephropathy
gut microbiota
febuxostat
astragaloside IV
uric acid
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1031509/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1031509/full

Similar Items